These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Nevirapine surprise.
    Author: Smart T.
    Journal: GMHC Treat Issues; 1996; 10(6/7):25. PubMed ID: 11363640.
    Abstract:
    The Food and Drug Administration (FDA) granted accelerated approval to Boehringer Ingelheim's nevirapine (Viramune) on June 7, 1996. Nevirapine is the ninth antiretroviral on the market. Results of BI 1046, which followed patients for one year, are reported. When used in triple combination therapy, nevirapine was effective in reducing viral load and maintaining CD4 counts. The FDA approved combining nevirapine with nucleoside analogs in adults. However, the FDA withheld the same approval with protease inhibitors due to indications that it damages liver function.
    [Abstract] [Full Text] [Related] [New Search]